Neoplasms Clinical Trial
Official title:
A Shared Care Approach for Seriously Ill Cancer Patients Between General Practice, Discharge Department and a Specialist Palliative Care Team
Verified date | January 2011 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | Denmark: Danish Dataprotection Agency |
Study type | Interventional |
Background:
Approximately one third of all deaths in Denmark are caused by cancer. Both Danish and
international research shows that the majority of terminally ill cancer patients wish to die
at home. In Denmark only about 25% has this wish fulfilled. The General Practitioner (GP)
has traditionally had the full responsibility for the palliative care of terminally ill
cancer patients. In recent years changes have been made to the organisation of palliative
care: some hospitals have set up specialised palliative care teams and in some areas of
Denmark hospices have been established.
Recent research defines a problem when it comes to communication between the hospital and
general practice when the patient is being discharged. This is often done in a way that can
cause the patient to feel "left in limbo", especially if it is not completely clear to the
patient and his or her relatives who has the responsibility for the palliative care.
Objective:
1. To describe consequences for patients, relatives and health care professionals of three
different ways of organising palliative care
2. To collect data which describes patients who are candidates to a shared care approach
between general practice and a specialised palliative care team
3. To collect data which describes the palliative phase (place of death and palliative
care, admissions to hospital, involvement of GP and district nurse etc.)
4. To describe terminally ill cancer patients and their relatives expectations of the
health care system
270 terminally ill cancer patients will be invited to take part in the study. Data will be
collected by interview with patients and questionnaires for patients, relatives and involved
health care professionals.
Status | Withdrawn |
Enrollment | 270 |
Est. completion date | November 2010 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: In order to be included the patients have to be diagnosed as suffering from terminal cancer. The patients should also: 1. Be 18 years or older 2. Be able to speak and write Danish fluently 3. Give written and spoken consent 4. Be able to manage in their own home, with or without the help of carers and district nurses 5. Be informed about the diagnosis, also that it is incurable 6. Be registered as suffering from a terminal illness or fulfil the criteria for this - Exclusion Criteria: Patients are excluded if they: 1. Have a low level of cognitive skills, which makes it difficult for them to fill in a questionnaire 2. Are residents of a nursing home at the time of inclusion 3. Are receiving oncologic treatment which requires attending an out-patients clinic regularly 4. Already have established contact with a specialist palliative care team at the time of inclusion - |
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus | Research Unit for General Practice, Aarhus University, The Specialist Palliative Care Team, Dept. of Oncology, Aarhus University Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patients wish for place of death and place of terminal care fulfilled | The patient will be asked about preference for place of death and place for terminal care at inclusion and a month later. At the time of death we will be able to establish weather the patient had his or her wishes fulfilled. | No | |
Primary | Relative amount of time spent in hospital in the terminal phase | At the patients time of death we will be able to count number of days spent in hospital using the hospitals electronic patient files. | No | |
Primary | A subjective measure of the patients symptoms and quality of life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire of Palliative care [EORTC-QLQ-15-PAL]) | Will be measured at the time of inclusion and a month later. | No | |
Secondary | Patient's satisfaction regarding the services of the GP, district nurse and local hospital | Will be measured at inclusion and one month later. | No | |
Secondary | Patient's experiences regarding cooperation and information sharing in the health care system. | Will be measured at inclusion and one month later. | No | |
Secondary | Relative's satisfaction regarding the services of the GP, district nurse and local hospital. | Will be measured at inclusion, one month later and 2 months after the patients death. | No | |
Secondary | Relative's experiences regarding cooperation and information sharing in the health care system. | Will be measured at inclusion, one month later and 2 months after the patients death. | No | |
Secondary | Relative's experiences regarding the palliative treatment of the patient. | Will be measured at inclusion, one month later and 2 months after the patients death. | No | |
Secondary | Subjective burden of relative (Burden Scale for Family Caregivers [BSFC]). | Will be measured at inclusion and one month later. | No | |
Secondary | GPs evaluation of the terminal phase. | Will be measured after the patients death. | No | |
Secondary | District nurses evaluation of the terminal phase. | Will be measured after the patients death. | No | |
Secondary | Hospital doctors evaluation of the terminal phase. | Will be measured after the patients death. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |